B-lymphocytes from malignant hyperthermia-susceptible patients have an increased sensitivity to skeletal muscle ryanodine receptor activators.
about
Malignant hyperthermiaCentral core disease: clinical, pathological, and genetic featuresPharmGKB summary: very important pharmacogene information for RYR1Functional defects in six ryanodine receptor isoform-1 (RyR1) mutations associated with malignant hyperthermia and their impact on skeletal excitation-contraction coupling.Malignant hyperthermia: a pharmacogenetic disorder.Eccentric contractions do not induce rhabdomyolysis in malignant hyperthermia susceptible mice.Variable myopathic presentation in a single family with novel skeletal RYR1 mutation.Gain of function in the immune system caused by a ryanodine receptor 1 mutation.Hypermetabolism in B-lymphocytes from malignant hyperthermia susceptible individuals.Functional properties of ryanodine receptors carrying three amino acid substitutions identified in patients affected by multi-minicore disease and central core disease, expressed in immortalized lymphocytes.Identification of a key determinant of ryanodine receptor type 1 required for activation by 4-chloro-m-cresol.An RYR1 mutation associated with malignant hyperthermia is also associated with bleeding abnormalities.Exercise-induced rhabdomyolysis and stress-induced malignant hyperthermia events, association with malignant hyperthermia susceptibility, and RYR1 gene sequence variations
P2860
Q21203008-4FD28A16-8EA8-40A0-B94E-45E3F6013B83Q24675329-860FAE31-9C1C-4F42-B6B6-5C471505F179Q28074804-609918DE-5938-462B-8533-DD4CE4C9F1C6Q34195030-39EC1CC2-4CF8-4618-AA73-FA72AFE845F9Q34883560-0A5D9970-1D09-4D7A-9623-AB4EE370A6E3Q36977089-B6BC37D3-0155-4758-8BE1-57E73FCA5846Q37042618-82908FD5-E540-4B9C-81D5-2F7F11815133Q37061543-FAD36582-9A06-4DD5-9B5E-2164635920CEQ41128547-498A5EE7-5DD7-434A-B978-736AB3165548Q41996021-0BA201C4-550C-40D2-9A24-D4BEB2E8F852Q44449789-44A84B79-51FA-4879-8E79-146D30D9A670Q47412008-9DA0C2C5-4EF0-4081-9AB2-074695A21C63Q59034021-84DD416E-AA83-4E06-85B1-F159DAED30B6
P2860
B-lymphocytes from malignant hyperthermia-susceptible patients have an increased sensitivity to skeletal muscle ryanodine receptor activators.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
B-lymphocytes from malignant h ...... ryanodine receptor activators.
@en
type
label
B-lymphocytes from malignant h ...... ryanodine receptor activators.
@en
prefLabel
B-lymphocytes from malignant h ...... ryanodine receptor activators.
@en
P2093
P2860
P356
P1476
B-lymphocytes from malignant h ...... ryanodine receptor activators
@en
P2093
P2860
P304
48077-48082
P356
10.1074/JBC.M107134200
P407
P577
2001-10-22T00:00:00Z